Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Stephen Lim"'
Autor:
Carley Turner, Laura Stampleman, Armando Sanchez, Shahrooz Eshaghian, Robert A. Moss, Ravindranath Patel, Youram Nassir, Stephen Lim, Gary T. Schwartz, Benjamin Eades, Jennifer To, Daisy Martinez, Robert Vescio, Tanya M. Spektor, Matthew Ghermezi, Regina A. Swift, James R. Berenson, Alberto Bessudo
Publikováno v:
Journal of Clinical Oncology. 37:8048-8048
8048 Background: Preclinical studies from our laboratory have demonstrated that ruxolitinib (RUX) in combination with lenalidomide (LEN) and dexamethasone shows marked anti-myeloma effects both in vitro and in vivo. Furthermore, MUC1 is responsible f
Autor:
Regina A. Swift, Robert Vescio, James R. Berenson, Robert A. Moss, Jennifer To, Tanya M. Spektor, Stephen Lim, Benjamin Eades, Gary T. Schwartz, Carley Turner, Shahrooz Eshaghian, Laura Stampleman
Publikováno v:
Journal of Clinical Oncology. 36:8005-8005
8005Background: Preclinical studies from our laboratory have demonstrated that ruxolitinib (RUX) in combination with lenalidomide (LEN) and dexamethasone shows marked anti-myeloma effects both in vitro and in vivo. Furthermore, MUC1 is responsible fo
Autor:
Tanya M. Spektor, Steven Jeffrey Hager, Mehdi M. Moezi, Robert A. Moss, Stephen Lim, Shahrooz Eshaghian, Alan Cartmell, Joseph Z. Ye, Tina Maluso, Alberto Bessudo, Regina A. Swift, G. Q. Chen, James R. Berenson, Jacob D. Bitran, Alexa Cohen, Teresa A. Coleman, John Stewart Hrom
Publikováno v:
Journal of Clinical Oncology. 35:8013-8013
8013 Background: The proteasome inhibitor (PI) ixazomib (Ixz) is the first orally administered PI approved for treating multiple myeloma (MM). It has shown clinical activity as a single agent and when used in other combinations. In this phase 1/2 tri